quantisnow
FeedTopReportsPricing
⌘K
Live feed
19:00:16·2047d
PRRelease
Gilead Sciences Inc. logo
Immunomedics, Inc. logo

SHAREHOLDER ALERT: WeissLaw LLP Investigates Immunomedics, Inc.

GILD· Gilead Sciences Inc.IMMU· Immunomedics, Inc.
Health Care
Full content unavailable. See the original source below.
Original source

Companies

  • GILD
    Gilead Sciences Inc.
    Health Care
  • IMMU
    Immunomedics, Inc.
    Health Care

Recent analyst ratings

  • Mar 10GILDUpdateJefferies$180.00
  • Feb 20GILDUpdateBarclays$155.00
  • Feb 11GILDUpdateNeedham$170.00
  • Jan 7GILDUpdateUBS$145.00
  • Nov 24GILDUpdateTruist$140.00
  • Nov 13GILDUpdateScotiabank$140.00

Related

  • PR1d
    Gilead Sciences to Release First Quarter 2026 Financial Results on Thursday, May 7, 2026
  • PR6d
    Gilead Receives All Required Regulatory Approvals for the Acquisition of Arcellx and Extends Tender Offer
  • INSIDER7d
    SEC Form 4 filed by Dickinson Andrew D
  • INSIDER7d
    SEC Form 4 filed by Mercier Johanna
  • PR9d
    PEPFAR and The Global Fund Make Additional Investment in Gilead's Lenacapavir for HIV Prevention to Further Expand Access
  • PR14d
    Tempus Announces Strategic Collaboration with Gilead to Advance Oncology R&D Through RWE
  • PR16d
    EQT Life Sciences to exit minority stake in Tubulis via sale to Gilead Sciences for up to USD 5.0 billion
  • PR16d
    Gilead to Acquire Tubulis Adding Potentially Best-in-Class Antibody-Drug Conjugate and Next Generation Platform to Further Strengthen Oncology Pipeline
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022